Magnesium Sulfate and Risk of Cerebral Palsy in Very Low-Birth-Weight Infants

Nelson, Karin B.

doi:10.1001/jama.1996.03540220067034

Cited by 31 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cette baisse de 50 % semblait réaliste considéré les réductions des taux de leucomalacie périven-triculaire et de paralysie cérébrale observées avec le MgSO 4 dans plusieurs études d'observation [14,15]. É tant attendu que 20 et 1 % des mères de prématurés donnent naissance respectivement, à des jumeaux ou des triplés, le nombre de mères à inclure a été calculé à 906.…”

Section: Taille De L'échantillon Et Conduite De L'essaiunclassified

See 1 more Smart Citation

Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul à deux ans : résultats de l’essai prospectif multicentrique contre placebo PREMAG

Marret

Marpeau

Follet-Bouhamed

et al. 2008

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

Section: Taille De L'échantillon Et Conduite De L'essaiunclassified

“…Ces propriétés pharmacologiques et les études d'observation humaine dans lesquelles ont été observé des bénéfices du traitement par MgSO 4 nous ont permis de proposer un essai thérapeutique randomisé [14,15].…”

Section: Intérêt Potentiel Du Magnésiumunclassified

Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul à deux ans : résultats de l’essai prospectif multicentrique contre placebo PREMAG

Marret

Marpeau

Follet-Bouhamed

et al. 2008

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

“…Case–control studies have suggested that maternal treatment shortly before birth may lower the risk of cerebral palsy in surviving very-low-birthweight infants 11–13. A recent randomised trial found some evidence to support this view 14.…”

Section: Introductionmentioning

confidence: 99%

The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for children at 18 months

2006

BJOG

143

View full text Add to dashboard Cite

Objective To assess the long-term effects of in utero exposure to magnesium sulphate for children whose mothers had pre-eclampsia.Design Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998(recruitment -2001, which compared magnesium sulphate with placebo.Setting Follow-up of children born at 125 centres in 19 countries across five continents.Population A total of 6922 children were born to women randomised before delivery at follow-up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow-up, of whom 3283 (73%) were contacted.Methods Assessment by questionnaire, with interview and neurodevelopmental testing of selected children.Main outcome measures Death or neurosensory disability at age of 18 months.Results Of those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90-1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40-1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities.Conclusions The lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months.

show abstract

“…Potential effects on the baby may also depend on gestational age at exposure to magnesium sulphate. Case control studies have suggested that maternal magnesium sulphate administration reduces the risk of cerebral palsy for low birthweight (<1500 g) infants, [15-17] although a recent study suggests such exposure may actually increase cerebral palsy [18]. There is also concern about a possible increase in paediatric mortality following exposure to magnesium sulphate [19].…”

Section: Introductionmentioning

confidence: 99%

The Magpie Trial follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]

2004

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

BackgroundThe Magpie Trial compared magnesium sulphate with placebo for women with pre-eclampsia. 10,141 women were recruited, 8804 before delivery. Overall, 9024 children were included in the analysis of outcome at discharge from hospital. Magnesium sulphate more than halved the risk of eclampsia, and probably reduced the risk of maternal death. There did not appear to be any substantive harmful effects on the baby, in the short term. It is now important to assess whether these benefits persist, and to provide adequate reassurance about longer term safety.The main objective of the Magpie Trial Follow Up Study is to assess whether in utero exposure to magnesium sulphate has a clinically important effect on the child's chance of surviving without major neurosensory disability. Other objectives are to assess long term outcome for the mother, and to develop and assess appropriate strategies for following up large numbers of children in perinatal trials.Study designFollow up is only feasible in selected centres. We therefore anticipate contacting 2800–3350 families, for 2435–2915 of whom the woman was randomised before delivery. A further 280–335 children would have been eligible for follow up if they had survived. The total sample size for the children is therefore 3080–3685, 2680–3210 of whom will have been born to women randomised before delivery.Families eligible for the follow up will be contacted, and surviving children screened using the Ages and Stages Questionnaires. Children who screen positive, and a sample of those who screen negative, will whenever possible have a paediatric and neurodevelopmental assessment. When women are contacted to ask how their child is, they will also be asked about their own health. The primary outcome is a composite measure of death or neurosensory disability for the child at 18 months.DiscussionThe Follow Up Study began in 2002, and now involves collaborators in 19 countries. Data collection will close at the end of 2003.

show abstract

Magnesium Sulfate and Risk of Cerebral Palsy in Very Low-Birth-Weight Infants

Cited by 31 publications

References 16 publications

Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul à deux ans : résultats de l’essai prospectif multicentrique contre placebo PREMAG

Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul à deux ans : résultats de l’essai prospectif multicentrique contre placebo PREMAG

The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for children at 18 months

The Magpie Trial follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]

Contact Info

Product

Resources

About